By using an efficient carrier, FGF21 administration attenuated cardiac fibrosis, resulting in decreased mRNA levels of cardiac hypertrophy and fibrosis markers in diabetic cardiomyopathy mice (96). This evidence concerns the gene FGF21 and cardiac hypertrophy.